skip to content

Department of Chemical Engineering and Biotechnology

 

The Department welcomes enquiries from industry, and others, about possible collaborations to tackle particular problems or research areas, whether these are suited to a short consultancy, a small experimental programme or to a longer term study requiring a major research effort. A particular feature of this Department is that staff members are always willing to form multi-disciplinary teams, with the relevant skills, which can be brought to bear on the problem of interest.

Many organisations have found that a partnership with the Department is the most effective way to help improve their scientific skills or understanding of specialist processes, to develop and test ideas for new products and manufacturing techniques, or to optimise, modernise and enhance existing systems. We offer flexible funding, intellectual property ownership, timing, personnel and management options to suit our client companies. Projects can either be funded directly, or a range of options exist whereby industrial effort, in cash or kind, is substantially leveraged by public funding. We also have the ability to locate and consult other experts within the University of Cambridge or elsewhere in academia, as needed.

Industrial collaboration has been an enduring strength of CEB, with ongoing partnerships with blue-chip companies including Schlumberger Gould Research, ExxonMobil, BP, BorgWarner, BASF, Boeing, Bayer and AstraZeneca. The Department has a long and distinguished record of developing innovative new science and its applications via industrial secondments, international outreach and influence, independent entrepreneurs, new lecturers with industrial experience and major University-wide partnerships, including for example with Nokia, Unilever, BP, Schlumberger, TATA and Boeing.

We are keenly aware of the need to manage projects carefully, so as to ensure that agreed objectives are achieved within the time and cost specified and the required reporting arrangements at specified milestones are satisfactory. We agree safeguards with regard to the handling of confidential information and we manage the ownership of intellectual property from the outset of projects.

 

Latest news

Multi-million pound research centre in AI to spark digital revolution in chemical industry

12 November 2020

The new Innovation Centre in Digital Molecular Technologies aims to accelerate access to pharmaceuticals, agrochemicals, functional molecules and molecular materials through machine learning and robotics-based synthesis.

Professor Sabine Bahn highlighted in Movers and Shakers in BioBusiness report

10 November 2020

Released today by BioBeat, the seventh annual Movers and Shakers in BioBusiness report highlights 30 examples of resourceful leaders in the UK bioscience sector. For the first time, this year’s Movers and Shakers also features nearly 200 alumni from previous reports, including our Professor of Neurotechnology, Sabine Bahn.

Psyomics secures £1.5m funding to transform mental health diagnosis in the UK

28 October 2020

Psyomics Ltd, a UK-based healthtech and Unviersity of Cambridge spin-out, has closed a £1.5 million funding round from existing and new investors to bring its mental health assessment and diagnosis platform, Censeo, to market in the UK.